Research Nester assesses the growth of the global nonalcoholic steatohepatitis (NASH) therapeutics market which is anticipated to be on account of the growing cases of obesity and both type-II diabetes & prediabetes.

New York – February 16, 2023 - Research Nester’s recent market research analysis on “Nonalcoholic Steatohepatitis (NASH) Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitors analysis and a detailed overview of the global nonalcoholic steatohepatitis (NASH) therapeutics market in terms of market segmentation by drug type, distribution channel, and by region.

The global nonalcoholic steatohepatitis (NASH) therapeutics market is estimated to grow majorly on account of the increased burden of obese population, and higher number of living with diabetes. According to the World Health Organization statistics, 39 million children, 340 million teenagers, and 650 million adults worldwide are obese. Moreover, by 2025, 167 million people and children are expected to be obese, according to predictions. Furthermore, the diabetic cases in the world is expected to reach to 640 million by 2030, and to 780 million by 2045.

Some of the major growth factors and challenges that are associated with the growth of the global nonalcoholic steatohepatitis (NASH) therapeutics market are:

Growth Drivers:

• Surging Prevalence of Liver Issues
• Rise in the Approvals of Various Drugs
• Increasing Burden of Obesity
• Higher Number of People Living with Diabetes
• Better Outcomes of Medication

Challenges:

The risk associated with NASH, the production of drugs is bit tricky and many people are still undiagnosed are some of the major factors anticipated to hamper the growth of the global nonalcoholic steatohepatitis (NASH) therapeutics market.

By drug type, the global nonalcoholic steatohepatitis (NASH) therapeutics market is segmented into vitamin E and pioglitazone, obeticholic acid (OCA), lanifibranor, semaglutide, resmetirom, aramchol, and others.  The vitamin E and pioglitazone segment is to garner the second highest revenue of USD 13,340.4 million by the end of 2035 by growing at a significant CAGR of more than 12.2% over the forecast period. Additionally, the segment garnered a revenue of USD 4,435.0 Million in 2022. The segment growth is expected on the account of growing trials and the effectivity of vitamin E and pioglitazone in treating nonalcoholic steatohepatitis (NASH).

By region, the North America nonalcoholic steatohepatitis (NASH) therapeutics market is to generate the highest revenue of USD 16,887.4 million by the end of 2035. The market in the region generated a revenue of USD 1,597.7 million in 2022. This growth is anticipated by the higher number of people suffering from non-alcoholic fatty liver diseases. Moreover, the market in the North America is expected to grow at a CAGR of 19.5% over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global nonalcoholic steatohepatitis (NASH) therapeutics market which includes company profiling of Pfizer, Inc., Inventiva, Galmed Pharmaceuticals Ltd., Novo Nordisk A/S, Madrigal Pharmaceuticals, Galectin Therapeutics, NGM Biopharmaceuticals, Brsitol-Myers Squibb Company, Can Fite, Zydus Lifesciences Ltd., and Mitsubishi Chemical Group Corporation.